Genpharmasec Ltd Announces Q1 FY2026 Financial Results and Confirms Operational Segments

Genpharmasec Ltd Announces Q1 FY2026 Financial Results and Confirms Operational Segments​

Genpharmasec Ltd has released its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results following a meeting held on August 11, 2026, alongside the independent auditor's review report and segment reporting details.

The company reported key financial outcomes across both its standalone performance and consolidated group results for the first quarter of the fiscal year ending March 31, 2027.

Standalone Financial Highlights (Quarter ended June 30, 2026)​

According to the unaudited standalone financial results, Genpharmasec Ltd recorded significant turnover and profit before taxability during the quarter. The company's total income for the quarter reached 457,550. This was achieved after generating revenue from operations of 44,744 in Q1 FY26.

The company reported a profit before tax (PBT) of 209.72. After accounting for all expenses and total tax expense of 33, the net profit for the period stood at 5,696. The unaudited results have been reviewed by the Audit Committee and approved by the Board of Directors.

Financial data from the standalone report is presented below:

Group and Consolidated Results​

The consolidated results of Genpharmasec Ltd and its subsidiaries showed robust activity across various operational areas. The Group recorded total income amounting to 500,834 for the quarter ended June 30, 2026, driven by revenue from operations totaling 497,103.

The consolidated statement indicated that the company reported a profit before tax of 2,577 after incurring total expenses of 17,001. Total tax expense for the quarter was 5,166. The final profit attributable to equity holders of the parent entity (Parent) stood at 2,598.

The financial performance across the operating segments provides granular insight into the company's business focus.

Segment Reporting Analysis​

Genpharmasec Ltd has segmented its operations according to Indian Accounting Standard 108. The reported segment results for Q1 FY26 are detailed below:


The Pharmaceuticals segment remains the primary driver of revenue for the Group in Q1 FY26, contributing significantly to the overall profitability structure. The results reflect the company's diversified operations across the Pharmaceutical, Laboratory Testing, and Manufacturing & Processing segments.

Stock Price Movement​

As trading closed on Tuesday, shares of Genpharmasec Ltd declined by 1.90%, settling at ₹1.03. The stock traded within a tight intraday range defined by a low of ₹1.02 and a high of ₹1.06.